- Home
- HCI vs ARQT Comparison
HCI vs ARQT Comparison
Compare HCI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- ARQT
- Stock Information
- Founded
- HCI 2006
- ARQT 2016
- Country
- HCI United States
- ARQT United States
- Employees
- HCI N/A
- ARQT N/A
- Industry
- HCI Property-Casualty Insurers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- HCI Finance
- ARQT Health Care
- Exchange
- HCI Nasdaq
- ARQT Nasdaq
- Market Cap
- HCI 1.2B
- ARQT 1.1B
- IPO Year
- HCI N/A
- ARQT 2020
- Fundamental
- Price
- HCI $111.59
- ARQT $10.14
- Analyst Decision
- HCI Buy
- ARQT Strong Buy
- Analyst Count
- HCI 5
- ARQT 4
- Target Price
- HCI $140.00
- ARQT $15.50
- AVG Volume (30 Days)
- HCI 147.0K
- ARQT 2.3M
- Earning Date
- HCI 11-07-2024
- ARQT 11-06-2024
- Dividend Yield
- HCI 1.43%
- ARQT N/A
- EPS Growth
- HCI 163.93
- ARQT N/A
- EPS
- HCI 11.94
- ARQT N/A
- Revenue
- HCI $750,846,000.00
- ARQT $138,708,000.00
- Revenue This Year
- HCI N/A
- ARQT $208.32
- Revenue Next Year
- HCI $11.25
- ARQT $48.56
- P/E Ratio
- HCI $9.37
- ARQT N/A
- Revenue Growth
- HCI 48.73
- ARQT 182.84
- 52 Week Low
- HCI $81.35
- ARQT $1.76
- 52 Week High
- HCI $124.00
- ARQT $13.17
- Technical
- Relative Strength Index (RSI)
- HCI 49.02
- ARQT 55.70
- Support Level
- HCI $106.03
- ARQT $8.90
- Resistance Level
- HCI $121.40
- ARQT $10.72
- Average True Range (ATR)
- HCI 5.52
- ARQT 0.70
- MACD
- HCI -0.84
- ARQT 0.05
- Stochastic Oscillator
- HCI 38.06
- ARQT 56.52
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are HCPCI insurance operations, TypTap Group, Real estate operations, and Corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.